Question explored with the scientific record
Side effects of beta blockers
The short version: beta blockers reliably slow the heart and lower blood pressure, and the same mechanism that helps is what causes most of the harm.
The most common side effects are the drug doing its job too well. In a one-year trial of 260 cirrhosis patients, carvedilol caused hypotension, bradycardia, and asthma in about 9 in 100, versus about 28 in 100 on propranolol [1]. In heart failure patients, dizziness and low blood pressure were common enough that switching from carvedilol to bisoprolol relieved dizziness in every affected patient and improved hypotension in 56% [4]. In a small akathisia study, 17% of propranolol users withdrew because of low blood pressure and slow heart rate [3].
| Drug / setting | Adverse events | Rate |
|---|---|---|
| Carvedilol, cirrhosis | Hypotension, bradycardia, asthma | 9.23% [1] |
| Propranolol, cirrhosis | Same | 27.69% [1] |
| Propranolol, akathisia | Withdrawal for hypotension/bradycardia | 17% [3] |
| Metoprolol, perioperative (POISE) | Higher all-cause mortality vs placebo | HR 1.33 [2] |
The serious harms are real and under-discussed. In the POISE surgical trial, metoprolol cut nonfatal heart attacks but raised overall death compared with placebo [2]. Stopping a beta blocker abruptly is its own hazard: a case-control study found roughly a four-to-sixfold jump in first coronary events in the month after running out [7], and withdrawal during acute heart failure tracked with higher in-hospital and 30-day death [6]. Beta blockers can also worsen breathing in COPD; propranolol dropped lung function far more than metoprolol [5], and they can trigger Raynaud-like finger vasospasm [8].
What this retrieval cannot see: long-term safety data, cancer or metabolic outcomes, and head-to-head comparisons against genuinely untreated patients for most indications. Those gaps are the search's limits, not proof of safety.
My call: beta blockers are worth it for clear indications like heart failure or post-heart-attack care, but the side-effect burden is real and dose-dependent, and abrupt stopping is dangerous. Confidence: moderate.
Sources used 8
-
Efficacy of propranolol versus carvedilol in prophylaxis of variceal bleeding: Randomized clinical trial.
Carvedilol more effectively prevents first variceal bleeding than propranolol in cirrhosis with medium/large esophageal varices, with fewer adverse effects over a 1-year follow-up in a randomized trial of 260 patients.
DOI: 10.29309/tpmj/2023.30.11.7540 -
Safety of perioperative β-blocker use: how do β-blockers compare in terms of side effects?
A comprehensive expert opinion review synthesizing randomized trials and guidelines on perioperative beta-blockade in noncardiac surgery, concluding that initiating low-dose beta-blockade well before surgery and titrating to heart rate reduces perioperative myocardial ischemia a…
DOI: 10.1517/14740338.2011.552500 -
Pharmacological management of antipsychotic-induced akathisia: an update and treatment algorithm
A narrative review reports limited, mixed evidence for akathisia treatments: propranolol showed no full remission in 31 patients, ICI-118,551 and biperiden showed no difference versus placebo, and anticholinergics lack reliable trials; mirtazapine trials reported no adverse even…
DOI: 10.1192/apt.bp.114.013797 -
Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension
This study investigates the effects of switching from carvedilol to bisoprolol in heart failure patients experiencing dizziness or hypotension, finding significant improvements in symptoms and left ventricular function after the switch.
DOI: 10.1016/j.jjcc.2013.01.009 -
Beta-Adrenoceptor Blockers and Terbutaline in Patients with Chronic Obstructive Lung Disease
Metoprolol caused less bronchial obstruction than propranolol in COPD patients; terbutaline improved FEV1 but did not prevent propranolol-induced deterioration.
DOI: 10.1378/chest.78.5.714 -
BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure
The BETAWIN-AHF study evaluates the impact of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure, finding that discontinuation is associated with increased in-hospital and 30-day mortality.
DOI: 10.1007/s00392-016-1014-9 -
The Relative Risk of Incident Coronary Heart Disease Associated With Recently Stopping the Use of β-Blockers
A population-based case-control study of hypertensive patients on antihypertensive therapy found that recently stopping beta-blocker treatment markedly increases the risk of a first coronary event, with a transient, potentially withdrawal-related effect strongest in the month af…
DOI: 10.1001/jama.1990.03440120075040 -
BETA‐ADRENERGIC BLOCKADE AND VASOSPASM
Three beta-blocker–treated patients with Raynaud-like digital vasospasm were studied to quantify changes in digital arterial pressure during cooling and withdrawal of beta-blockade, revealing that beta-adrenergic blockade can enhance digital vasoconstriction via increased alpha-…
DOI: 10.1111/j.0954-6820.1979.tb00739.x